Respiratory syncytial virüs infections in neonates and infants
Authors:
- 29 July 2018
- journal article
- review article
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 53 (2) , 63-70
Abstract
Respiratory syncytial virus is one of the major causes of respiratory tract infections during infancy with high rates of hospitalization and mortality during the first years of life. It is the most common cause of acute bronchiolitis and viral pneumonia in children below two years of age and second the most common cause of postneonatal infant mortality all around the world following malaria. In addition, the virus has been causally linked to recurrent wheezing and associated with pediatric asthma. The respiratory syncytial virus infections tend to be severe in high risk patients such as patients below six months of age, with prematurity, congenital heart diseases, neuromuscular diseases and immune deficiencies. No specific treatment is available for respiratory syncytial virus infections to date. Severe cases require supportive therapy, mainly oxygen supplementation and hydration, and less frequently, ventilatory support. Because there is no vaccine to prevent respiratory syncytial virus infections or clinically effective treatment to administer to children with respiratory syncytial virus infection, immunoprophylaxis with palivizumab is currently the only method for reducing morbidity associated with severe respiratory syncytial virus in high-risk infants.Keywords
This publication has 46 references indexed in Scilit:
- Epidemiology of hospitalization for acute bronchiolitis in children: differences between RSV and non-RSV bronchiolitisEuropean Journal of Clinical Microbiology & Infectious Diseases, 2012
- Cord Blood Vitamin D Deficiency Is Associated With Respiratory Syncytial Virus BronchiolitisPediatrics, 2011
- Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysisThe Lancet, 2010
- Respiratory Viral Infections in Infants: Causes, Clinical Symptoms, Virology, and ImmunologyClinical Microbiology Reviews, 2010
- Motavizumab for Prophylaxis of Respiratory Syncytial Virus in High-Risk Children: A Noninferiority TrialPediatrics, 2010
- The Burden of Respiratory Syncytial Virus Infection in Young ChildrenNew England Journal of Medicine, 2009
- Comparative Effects of Two Neutralizing Anti-Respiratory Syncytial Virus (RSV) Monoclonal Antibodies in the RSV Murine Model: Time versus PotencyAntimicrobial Agents and Chemotherapy, 2005
- The transmission dynamics of groups A and B human respiratory syncytial virus (hRSV) in England & Wales and Finland: seasonality and cross-protectionEpidemiology and Infection, 2005
- Reduction of Respiratory Syncytial Virus Hospitalization Among Premature Infants and Infants With Bronchopulmonary Dysplasia Using Respiratory Syncytial Virus Immune Globulin ProphylaxisPediatrics, 1997
- Possible Transmission by Fomites of Respiratory Syncytial VirusThe Journal of Infectious Diseases, 1980